Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 300

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial

Gray, William A, Keirse, Koen, Soga, Yoshimitsu, Benko, Andrew, Babaev, Anvar, Yokoi, Yoshiaki, Schroeder, Henrik, Prem, Jeffery T, Holden, Andrew, Popma, Jeffrey, Jaff, Michael R, Diaz-Cartelle, Juan, Müller-Hülsbeck, Stefan, Albrecht, Thomas, Ando, Kenji, Babaev, Anvar, Bacharach, Michael J, Bachinsky, William, Bajakian, Danielle, Beasley, Robert, Benenati, James, Benko, Andrew, Burket, Mark, Cardenas, Joseph, Das, Tony, De Martino, Randall, Deutschmann, Hannes, Dulas, Daniel, Feldman, Robert, Fugate, Mark, Garcia, Lawrence, Golzar, Jaafer, Gutta, Rao, Hall, Patrick, Hawkins, Stewart, Henao, Steve, Herdrich, Benjamin, Hirano, Keisuke, Holden, Andrew, Jaalouk, Safwan, Janzer, Sean, Kawasaki, Daizo, Keirse, Koen, Khatib, Yazan, Kichikawa, Kimihiko, Korngold, Ethan, Loewe, Christian, Lopez, Louis, Lui, Henry, Mano, Toshiaki, Mendes, Robert, Miyamoto, Akira, Müller-Hülsbeck, Stefan, Nakamura, Masato, O'Connor, David, Ohki, Takao, Park, James, Powell, Richard, Pratsos, Antonis, Prem, Jeffery, Rao, Vikram, Rashid, John, Rhee, Robert, Ricci, Jason, Scheinert, Dierk, Schroë, Herman, Schroeder, Henrik, Simon, Peter O, Singh, Gagan, Tan, Kongteng, Tolerico, Paul, Vasudevan, Thodur, Vermassen, Frank, Werner, Martin, Wiechmann, Bret, Yokoi, Hiroyoshi, Yokoi, Yoshiaki, Zeller, Thomas · 2018 · The Lancet

Abstract

BACKGROUND The clinical effect of a drug-eluting stent in the femoropopliteal segment has not been investigated in a randomised trial with a contemporary comparator. The IMPERIAL study sought to compare the safety and efficacy of the polymer-coated, paclitaxel-eluting Eluvia stent with the polymer-free, paclitaxel-coated Zilver PTX stent for treatment of femoropopliteal artery segment lesions. METHODS In this randomised, single-blind, non-inferiority study, patients with symptomatic lower-limb ischaemia manifesting as claudication (Rutherford category 2, 3, or 4) with atherosclerotic lesions in the native superficial femoral artery or proximal popliteal artery were enrolled at 65 centres in Austria, Belgium, Canada, Germany, Japan, New Zealand, and the USA. Patients were randomly assigned (2:1) with a site-specific, web-based randomisation schedule to receive treatment with Eluvia or Zilver PTX. All patients, site personnel, and investigators were masked to treatment assignment until all patients had completed 12 months of follow-up. The primary efficacy endpoint was primary patency (defined as a peak systolic velocity ratio ≤2·4, without clinically driven target lesion revascularisation or bypass of the target lesion) and the primary safety endpoint was major adverse events (ie, all causes of death through 1 month, major amputation of target limb through 12 months, and target lesion revascularisation through 12 months). We set a non-inferiority margin of -10% at 12 months. Primary non-inferiority analyses were done when the minimum sample size required for adequate statistical power had completed 12 months of follow-up. The primary safety non-inferiority analysis included all patients who had completed 12 months of follow-up or had a major adverse event through 12 months. This trial is registered with ClinicalTrials.gov, number NCT02574481. FINDINGS Between Dec 2, 2015, and Feb 15, 2017, 465 patients were randomly assigned to Eluvia (n=309) or to Zilver PTX (n=156). Non-inferiority was shown for both efficacy and safety endpoints at 12 months: primary patency was 86·8% (231/266) in the Eluvia group and 81·5% (106/130) in the Zilver PTX group (difference 5·3% [one-sided lower bound of 95% CI -0·66]; p<0·0001). 259 (94·9%) of 273 patients in the Eluvia group and 121 (91·0%) of 133 patients in the Zilver PTX group had not had a major adverse event at 12 months (difference 3·9% [one-sided lower bound of 95% CI -0·46]; p<0.0001). No deaths were reported in either group. One patient in the Eluvia group had a major amputation and 13 patients in each group required target lesion revascularisation. INTERPRETATION The Eluvia stent was non-inferior to the Zilver PTX stent in terms of primary patency and major adverse events at 12 months after treatment of patients for femoropopliteal peripheral artery disease. FUNDING Boston Scientific.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)32262-1

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 300

Metadata

Authors
Gray, W. A., Keirse, K., Soga, Y., Benko, A., Babaev, A., Yokoi, Y., Schroeder, H., Prem, J. T., Holden, A., Popma, J., Jaff, M. R., Diaz-Cartelle, J., Müller-Hülsbeck, S., Albrecht, T., Ando, K., Babaev, A., Bacharach, M. J., Bachinsky, W., Bajakian, D., Beasley, R., Benenati, J., Benko, A., Burket, M., Cardenas, J., Das, T., De Martino, R., Deutschmann, H., Dulas, D., Feldman, R., Fugate, M., Garcia, L., Golzar, J., Gutta, R., Hall, P., Hawkins, S., Henao, S., Herdrich, B., Hirano, K., Holden, A., Jaalouk, S., Janzer, S., Kawasaki, D., Keirse, K., Khatib, Y., Kichikawa, K., Korngold, E., Loewe, C., Lopez, L., Lui, H., Mano, T., Mendes, R., Miyamoto, A., Müller-Hülsbeck, S., Nakamura, M., O'Connor, D., Ohki, T., Park, J., Powell, R., Pratsos, A., Prem, J., Rao, V., Rashid, J., Rhee, R., Ricci, J., Scheinert, D., Schroë, H., Schroeder, H., Simon, P. O., Singh, G., Tan, K., Tolerico, P., Vasudevan, T., Vermassen, F., Werner, M., Wiechmann, B., Yokoi, H., Yokoi, Y., & Zeller, T.
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-10
Volume
392
Issue
10157
Pages
1541-1551
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2891944790
Cited by
300
References
18
FWCI
27.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)32262-1
The paper
Gray, W. A., Keirse, K., Soga, Y., Benko, A., Babaev, A., Yokoi, Y., Schroeder, H., Prem, J. T., Holden, A., Popma, J., Jaff, M. R., Diaz-Cartelle, J., Müller-Hülsbeck, S., Albrecht, T., Ando, K., Babaev, A., Bacharach, M. J., Bachinsky, W., Bajakian, D., . . . Zeller, T. (2018). A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)32262-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.